A plot to solve the ‘whack-a-mole’ of drug discovery

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with some hotly anticipated news from Vertex Pharmaceuticals, a closer look at the latest FTC controversy, and a detailed look at what it’s like to actually receive a gene therapy.

The need-to-know this morning

• Pfizer provided financial guidance for 2024 that fell well below Wall Street expectations. Shares are trading lower in the pre-market session.
• Alnylam Pharmaceuticals is meeting with investors and analysts today to discuss the company’s R&D programs and outlook.

Vertex non-opioid drug reduces chronic nerve pain

Vertex Pharmaceuticals said Wednesday that an experimental drug reduced pain in people with diabetes who have chronic nerve pain — mid-stage study results that support the biotech company’s efforts to develop an effective painkiller without the addictive potential of opioids.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In